Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913105 | 0.84 | CHRM2 (0.77) | CHRM2TP53HTTSCN8ACA12 | |
| SCHEMBL4916612 | 0.82 | CHRM2 (0.81) | CHRM2TP53HTTCA12CA2 | |
| SCHEMBL4912089 | 0.82 | CHRM2 (0.81) | CHRM2TP53HTTCA12CA2 | |
| SCHEMBL5034679 | 0.82 | CHRM2 (0.81) | CHRM2TP53HTTCA12CA2 | |
| SCHEMBL13900508 | 0.81 | CHRM2 (0.56) | CHRM2TP53HTTHPGDALDH1A1 | |
| SCHEMBL17282103 | 0.80 | CA12 (0.69) | CA12CA2 | |
| SCHEMBL21799554 | 0.80 | CHRM2 (0.40) | CHRM2CA12CA2 | |
| SCHEMBL13965834 | 0.80 | MPO (0.54) | HTTSCN8ACA2HPGDMEN1 | |
| SCHEMBL40401 | 0.80 | CHRM2 (0.69) | CHRM2TP53HTTHPGDALDH1A1 | |
| SCHEMBL13965857 | 0.79 | NPC1 (0.43) | CHRM2HTTHPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | CHRM2 4242/4885TP53 3810/4885HTT 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.